Knowthestock.com
BPMC - Blueprint Medicines Corp

Sell

Weak GrowthEarnings/Profit is Negative

30%

based on last 5 year data.
Income Statement is WEAK
Revenue Growth is -86.79%
Operating Income is Negative
Net Income is Negative
Earnings Per Share (EPS) is Negative
Net Margin is -383.58%
Balance Sheet is STRONG
Current Asset to Current Liability Ratio is 6.45
Debt Ratio is 0.16
Current Debt to Net Income Ratio not available
Total Debt to Total Assets Ratio is 0.0
Cash Flow is WEAK
Cash from Operations is Negative
Capital Expenditure not available
Net Increase in Cash is Negative
Long Term Score Trend is POSITIVE
Investment Risk is High
based on last 4 quarter data.
Unless specified, all values are in USD Millions. Data extracted from SEC Filing and are subject to processing and input errors.
Blueprint Medicines Corp (BPMC) - www.blueprintmedicines.com
Blueprint Medicines is a global precision therapy company that invents life-changing medicines for people with cancer and hematologic disorders. Applying an approach that is both precise and agile, the company creates therapies that selectively target genetic drivers, with the goal of staying one step ahead across stages of disease. Since 2011, Blueprint has leveraged its research platform, including expertise in molecular targeting and world-class drug design capabilities, to rapidly and reproducibly translate science into a broad pipeline of precision therapies. Today, the company is delivering its approved medicines to patients in the United States and Europe, and the company is globally advancing multiple programs for genomically defined cancers, systemic mastocytosis, and cancer immunotherapy.
Exchange - NASDAQ
Industry - Pharmaceutical Preparation Manufacturing
Sector - Manufacturing
CEO - Jeffrey Albers
Employees - 429
    Close


Disclaimer - Investment in securities involves substantial risk and could result in significant loss. It is not suitable for every investor. Before acting on information on this website, you should consider whether it is suitable for your particular circumstances and strongly consider seeking advice from your own financial or investment adviser. We may own some of the securities mentioned in this website.
Know the Stock © 2021 and future.